Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma

Civil Hospices of Lyon

Status: Completed

Conditions: Hodgkin Lymphoma

Treatments: Biological: Evaluate the improvement in response from the end of anti-PD-1 monotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT03664323

Anti-PD-1 Hodgkin

Details and patient eligibility

About

Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti-PD-1 is not well known.

In this context, the optimal treatment for patients who failed after anti-PD-1 therapy is an issue. To better assess their outcome, the investigators retrospectively analyzed the characteristics and outcome of patients from 14 LYSA (The Lymphoma Study Association) centers who lost response to anti-PD-1 therapy and received additional CT.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Initial diagnosis of classical HL
• Optional histopathology confirmation of relapse/refractory HL, (2) age ≥ 18 years
• Eastern Cooperative Oncology Group (ECOG) Performance Status from 0 to 2
• Patients must be have received: at least 2 prior regimens and have received or be ineligible for autologous stem cell transplant and must have received prior BV, and at least 2 cycles of single agent anti-PD-1 as last treatment before entering the study,
• Patients must have inadequate response to anti-PD-1 monotherapy (progressive disease or partial response according to Lugano criteria) with at least one hypermetabolic lesion over the liver and mediastinum background at time of inclusion in the study
• Previous allogeneic stem cell transplant was allowed. Patients treated with radiotherapy alone after anti-PD1 or combined with anti-PD1 treatment were not included in the study.

Exclusion criteria

• radiotherapy in the treatment after anti-PD1

Trial design

30 participants in 2 patient groups

Group 1 Sequential strategy

Description:

Patients for whom anti-PD-1 therapy was stopped with the introduction of a new treatment line (19 patients, 63%).

Treatment:

Biological: Evaluate the improvement in response from the end of anti-PD-1 monotherapy

Group 2 Concomitant strategy

Description:

Patients for whom a combination of CT with anti-PD-1 therapy was initiated (11 patients, 37 %).

Treatment:

Biological: Evaluate the improvement in response from the end of anti-PD-1 monotherapy